<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0001635'>Heart failure</z:hpo> is a growing cause of morbidity and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Cardiac phosphatidylinositol 3-kinase signaling promotes cardiomyocyte survival and function, but it is paradoxically activated in <z:hpo ids='HP_0001635'>heart failure</z:hpo>, suggesting that <z:hpo ids='HP_0011010'>chronic</z:hpo> activation of this pathway may become maladaptive </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we investigated the downstream phosphatidylinositol 3-kinase effector, serum- and <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi>-regulated kinase-1 (SGK1), in <z:hpo ids='HP_0001635'>heart failure</z:hpo> and its complications </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: We found that cardiac SGK1 is activated in human and murine <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We investigated the role of SGK1 in the heart by using cardiac-specific expression of constitutively active or dominant-negative SGK1 </plain></SENT>
<SENT sid="5" pm="."><plain>Cardiac-specific activation of SGK1 in mice increased mortality, cardiac dysfunction, and <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The proarrhythmic effects of SGK1 were linked to biochemical and functional changes in the cardiac <z:chebi fb="199" ids="26708">sodium</z:chebi> channel and could be reversed by treatment with ranolazine, a blocker of the late <z:chebi fb="199" ids="26708">sodium</z:chebi> current </plain></SENT>
<SENT sid="7" pm="."><plain>Conversely, cardiac-specific inhibition of SGK1 protected mice after hemodynamic stress from <z:mp ids='MP_0003045'>fibrosis</z:mp>, <z:hpo ids='HP_0001635'>heart failure</z:hpo>, and <z:chebi fb="199" ids="26708">sodium</z:chebi> channel alterations </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: SGK1 appears both necessary and sufficient for key features of adverse ventricular remodeling and may provide a novel therapeutic target in <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e> </plain></SENT>
</text></document>